Global Biosimilar Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Biosimilar Market 2024 by Company, Regions, Type and Application, Forecast to 2030

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.

Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.

In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.

According to our (Global Info Research) latest study, the global Biosimilar market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.

In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.

This report is a detailed and comprehensive analysis for global Biosimilar market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Biosimilar market size and forecasts, in consumption value ($ Million), 2019-2030

Global Biosimilar market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Biosimilar market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Biosimilar

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Biosimilar market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao, United Laboratory, 3SBIO, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Biosimilar market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others

Market segment by Application
Cancer
Immunological Diseases
Diabetes
Others

Market segment by players, this report covers
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Biosimilar product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Biosimilar, with revenue, gross margin, and global market share of Biosimilar from 2019 to 2024.

Chapter 3, the Biosimilar competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Biosimilar market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Biosimilar.

Chapter 13, to describe Biosimilar research findings and conclusion.